{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:16:40Z","timestamp":1776543400710,"version":"3.51.2"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.neuropharm.2021.108590","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T10:58:14Z","timestamp":1620471494000},"page":"108590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Nalmefene, a mu opioid receptor antagonist\/kappa opioid receptor partial agonist, potentiates cocaine motivation but not intake with extended access self-administration in adult male mice"],"prefix":"10.1016","volume":"192","author":[{"given":"Kyle A.","family":"Windisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-1293","authenticated-orcid":false,"given":"Michelle","family":"Morochnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-366X","authenticated-orcid":false,"given":"Brian","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-9091","authenticated-orcid":false,"given":"Mary Jeanne","family":"Kreek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108590_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00213-005-2180-z","article-title":"Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function","volume":"180","author":"Ahmed","year":"2005","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0091-3057(96)00445-5","article-title":"A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement","volume":"57","author":"Arnold","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108590_bib3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41386-018-0125-6","article-title":"Sex differences in neural mechanisms mediating reward and addiction","volume":"44","author":"Becker","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib5","doi-asserted-by":"crossref","first-page":"PL85","DOI":"10.1016\/0024-3205(92)90105-X","article-title":"Opioidergic modulation of cocaine conditioned place preferences","volume":"50","author":"Bilsky","year":"1992","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1017\/S1461145707007705","article-title":"Effects of naltrexone on cocaine- and sucrose-seeking behaviour in response to associated stimuli in rats","volume":"11","author":"Burattini","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)24984-9","article-title":"Effects of naltrexone on intravenous cocaine self-administration in rats during food satiation and deprivation","volume":"238","author":"Carroll","year":"1986","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-1781(93)90084-T","article-title":"Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study","volume":"47","author":"Chappell","year":"1993","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2021.108590_bib9","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0022-3565(25)39443-7","article-title":"Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats","volume":"267","author":"Comer","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib10","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/npp.2013.143","article-title":"Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers","volume":"38","author":"Comer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02244173","article-title":"Opiate antagonists reduce cocaine but not nicotine self-administration","volume":"104","author":"Corrigall","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(25)20871-0","article-title":"Food deprivation and acquisition of intravenous cocaine self-administration in rats: effect of naltrexone and haloperidol","volume":"251","author":"De Vry","year":"1989","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0091-3057(90)90019-E","article-title":"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors","volume":"37","author":"deHaven-Hudkins","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108590_bib14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0022-3565(25)39324-9","article-title":"Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies","volume":"266","author":"Devine","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/j.1552-4604.1987.tb02191.x","article-title":"Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist","volume":"27","author":"Dixon","year":"1987","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-020-05543-7","article-title":"Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice","author":"Dunn","year":"2020","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib17","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","article-title":"Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses","volume":"10","author":"Dunn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1460-9568.2009.07065.x","article-title":"The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system","volume":"31","author":"Espana","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF00428151","article-title":"Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems","volume":"78","author":"Ettenberg","year":"1982","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/clpt.1986.220","article-title":"Prolonged blockade of opioid effect with oral nalmefene","volume":"40","author":"Gal","year":"1986","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.euroneuro.2004.11.004","article-title":"Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexone","volume":"15","author":"Gerrits","year":"2005","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2021.108590_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00213-012-2949-9","article-title":"Attenuation of cocaine and heroin seeking by mu-opioid receptor antagonism","volume":"227","author":"Giuliano","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neubiorev.2020.06.006","article-title":"Opposite regulation of conditioned place preference and intravenous drug self-administration in rodent models: motivational and non-motivational examples","volume":"116","author":"Green","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2021.108590_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pbb.2007.04.023","article-title":"Intravenous cocaine self-administration: individual differences in male and female C57BL\/6J mice","volume":"87","author":"Griffin","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108590_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/YIC.0000000000000069","article-title":"Treatment of cocaine craving with as-needed nalmefene, a partial kappa opioid receptor agonist: first clinical experience","volume":"30","author":"Grosshans","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0022-3565(25)13070-X","article-title":"The effects of eticlopride and naltrexone on responding maintained by food, cocaine, heroin and cocaine\/heroin combinations in rats","volume":"277","author":"Hemby","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib27","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/sj.npp.1300790","article-title":"Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing","volume":"30","author":"Ingman","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/adb.12513","article-title":"Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption","volume":"23","author":"Kallupi","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib29","series-title":"Recent Developments in Alcoholism","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4899-1648-8_11","article-title":"Neuropharmacology of cocaine and ethanol dependence","author":"Koob","year":"1992"},{"key":"10.1016\/j.neuropharm.2021.108590_bib30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0024-3205(89)90589-4","article-title":"Role of opioid antagonists in treating intravenous cocaine abuse","volume":"44","author":"Kosten","year":"1989","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib31","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrd897","article-title":"Pharmacotherapy of addictions","volume":"1","author":"Kreek","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2021.108590_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bcp.12805","article-title":"Population pharmacokinetics of nalmefene in healthy subjects and its relation to mu-opioid receptor occupancy","volume":"81","author":"Kyhl","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib33","first-page":"175","article-title":"Binding of a new opiate antagonist, nalmefene, to rat brain membranes","volume":"7","author":"Michel","year":"1985","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0090-9556(25)06015-5","article-title":"Disposition of (15,16-3H)naltrexone in the central nervous system of the rat","volume":"4","author":"Misra","year":"1976","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2021.108590_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0091-3057(98)00150-6","article-title":"The effects of the naltrexone implant on rodent social interactions and cocaine-induced conditioned place preference","volume":"62","author":"Mitchem","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108590_bib36","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2021.108590_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-010-1899-3","article-title":"Dose preference and dose escalation in extended-access cocaine self-administration in Fischer and Lewis rats","volume":"211","author":"Picetti","year":"2010","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0024-3205(89)90418-9","article-title":"Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats","volume":"45","author":"Porrino","year":"1989","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0924-977X(98)00009-1","article-title":"Naltrexone affects cocaine self-administration in naive rats through the ventral tegmental area rather than dopaminergic target regions","volume":"9","author":"Ramsey","year":"1999","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2021.108590_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0924-977X(90)90012-Y","article-title":"Chronic pretreatment with naltrexone facilitates acquisition of intravenous cocaine self-administration in rats","volume":"1","author":"Ramsey","year":"1990","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2021.108590_bib41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0091-3057(91)90090-O","article-title":"Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats","volume":"40","author":"Ramsey","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108590_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lfs.2010.10.007","article-title":"Sex differences in kappa opioid pharmacology","volume":"88","author":"Rasakham","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050454","article-title":"Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers","volume":"134","author":"Reith","year":"1997","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0024-3205(91)90248-A","article-title":"Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat","volume":"49","author":"Richardson","year":"1991","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0022-3565(25)10640-X","article-title":"Behavioral and biochemical evidence of opioidergic involvement in cocaine sensitization","volume":"274","author":"Sala","year":"1995","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.drugalcdep.2013.12.015","article-title":"A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone","volume":"136","author":"Schmitz","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2021.108590_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0306-4603(00)00098-8","article-title":"Naltrexone and relapse prevention treatment for cocaine-dependent patients","volume":"26","author":"Schmitz","year":"2001","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuropharm.2021.108590_bib48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0091-3057(03)00157-6","article-title":"Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans","volume":"75","author":"Sofuoglu","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108590_bib49","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1124\/mol.114.096503","article-title":"A novel method for analyzing extremely biased agonism at G protein-coupled receptors","volume":"87","author":"Stahl","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib50","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"key":"10.1016\/j.neuropharm.2021.108590_bib51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-5198(19)39723-9","article-title":"The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference","volume":"58","author":"Suzuki","year":"1992","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib52","article-title":"Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction","author":"Teklezgi","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuropharm.2019.03.019","article-title":"Male and female mice develop escalation of heroin intake and dependence following extended access","volume":"151","author":"Towers","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib54","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00213-017-4647-0","article-title":"Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats","volume":"234","author":"Valenza","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00213-019-05444-4","article-title":"Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat","volume":"237","author":"Valenza","year":"2020","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib56","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0090-9556(25)06161-6","article-title":"Metabolism and disposition of naltrexone in man after oral and intravenous administration","volume":"9","author":"Wall","year":"1981","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2021.108590_bib57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FBP.0b013e328331ba30","article-title":"Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice","volume":"20","author":"Ward","year":"2009","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108590_bib58","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1124\/jpet.106.113340","article-title":"Effects of dose and session duration on cocaine self-administration in rats","volume":"320","author":"Wee","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108590_bib59","doi-asserted-by":"crossref","first-page":"146ra110","DOI":"10.1126\/scitranslmed.3003948","article-title":"A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence","volume":"4","author":"Wee","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2021.108590_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuropharm.2018.07.025","article-title":"Naltrexone and nalmefene attenuate cocaine place preference in male mice","volume":"140","author":"Windisch","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib61","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1111\/j.1460-9568.2005.04159.x","article-title":"Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats","volume":"21","author":"Xi","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib62","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00213-003-1688-3","article-title":"Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice","volume":"172","author":"Zhang","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00213-003-1716-3","article-title":"Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice","volume":"173","author":"Zhang","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib64","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00213-013-3306-3","article-title":"Extended access oxycodone self-administration and neurotransmitter receptor gene expression in the dorsal striatum of adult C57BL\/6 J mice","volume":"231","author":"Zhang","year":"2014","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108590_bib65","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/npp.2014.286","article-title":"Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self-administration behavior compared with wild-type mice","volume":"40","author":"Zhang","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108590_bib66","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1523\/JNEUROSCI.3923-05.2006","article-title":"Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32","volume":"26","author":"Zhang","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108590_bib67","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1369-1600.2011.00329.x","article-title":"Extended access cocaine self-administration differentially activates dorsal raphe and amygdala corticotropin-releasing factor systems in rats","volume":"17","author":"Zorrilla","year":"2012","journal-title":"Addiction Biol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:13:12Z","timestamp":1758438792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821001441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":67,"alternative-id":["S0028390821001441"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108590","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nalmefene, a mu opioid receptor antagonist\/kappa opioid receptor partial agonist, potentiates cocaine motivation but not intake with extended access self-administration in adult male mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108590"}}